DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
968
TIMOLUMAB
1
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid
Unknown
TIMOLUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
UJO03RO3K6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SOFITUZUMAB VEDOTIN
1
Antibody
Investigational
Unknown
Unknown
Ovarian Neoplasms; Pancreatic Neoplasms
Mucin-16 binding agent
SOFITUZUMAB VEDOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
2X3CKG601L
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MLN-01
1
Antibody
Investigational
Unknown
Unknown
Unknown
Integrin beta-2 inhibitor
MLN-01
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HUM195
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HUM195
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SONTUZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 other
SONTUZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AD-439
1
Antibody
Investigational
Unknown
Unknown
Unknown
Envelope polyprotein GP160 inhibitor
AD-439
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MORAB-028
1
Antibody
Investigational
Unknown
Unknown
Melanoma
Disialoganglioside GD2 cross-linking agent
MORAB-028
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PONSEGROMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
PONSEGROMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PIMURUTAMAB
1
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell
Unknown
PIMURUTAMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
5V1Y8T4RB6
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIRZOTAMAB CLEZUTOCLAX
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
MIRZOTAMAB CLEZUTOCLAX
×
Maximum Phase:
1
First Approval:
None
UNII:
TY49T0B03B
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LMB-7
1
Antibody
Investigational
Unknown
Unknown
Central Nervous System Neoplasms
Lewis Y antigen binding agent
LMB-7
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RO6958688
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RO6958688
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MONO-DGA-RFB4
1
Antibody
Investigational
Unknown
Unknown
Lymphoma
CD22 binding agent
MONO-DGA-RFB4
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BOS161721
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BOS161721
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SAR-1349
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
SAR-1349
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CNTO-5825
1
Antibody
Investigational
Unknown
Unknown
Unknown
Interleukin-13 inhibitor
CNTO-5825
×
Maximum Phase:
1
First Approval:
None
UNII:
JYB0ILB7HU
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DUVORTUXIZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
DUVORTUXIZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
J545GSE96Y
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CSL-360
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Interleukin-3 receptor subunit alpha inhibitor
CSL-360
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-639
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MEDI-639
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VANDORTUZUMAB VEDOTIN
1
Antibody
Investigational
Unknown
Unknown
Prostatic Neoplasms, Castration-Resistant
Metalloreductase STEAP1 binding agent
VANDORTUZUMAB VEDOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
44OUQ00D1U
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KHK-2866
1
Antibody
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Proheparin-binding EGF-like growth factor inhibitor
KHK-2866
×
Maximum Phase:
1
First Approval:
None
UNII:
111EN0IJ7C
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LINTUZUMAB ACTINIUM AC-225
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
LINTUZUMAB ACTINIUM AC-225
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ONGERICIMAB
1
Antibody
Investigational
Unknown
Unknown
Hypercholesterolemia; Hyperlipidemias
Unknown
ONGERICIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
X126G5DZ36
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AVIZAKIMAB
1
Antibody
Investigational
Unknown
Unknown
Lupus Erythematosus, Systemic
Unknown
AVIZAKIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
4H3BBE5WVK
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ATINUMAB
1
Antibody
Investigational
Unknown
Unknown
Spinal Cord Injuries
Reticulon-4 inhibitor
ATINUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
9UBQ62RW32
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-811
1
Antibody
Investigational
Unknown
Unknown
Psoriasis
Interferon gamma inhibitor
AMG-811
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BEPRANEMAB
1
Antibody
Investigational
Unknown
Unknown
Supranuclear Palsy, Progressive; Alzheimer Disease
Unknown
BEPRANEMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
9M1GV6L389
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FARALIMOMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Interferon alpha-1/13 binding agent
FARALIMOMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ZIRALIMUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Basigin inhibitor
ZIRALIMUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GLEMBATUMUMAB
1
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Melanoma
Transmembrane glycoprotein NMB binding agent
GLEMBATUMUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
WEC7MEM1BR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-191
1
Antibody
Investigational
Unknown
Unknown
Severe Combined Immunodeficiency
Stem cell growth factor receptor inhibitor
AMG-191
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNX-100
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
TNX-100
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEDI-4212
1
Antibody
Investigational
Unknown
Unknown
Dermatitis, Atopic; Rhinitis, Allergic, Seasonal
Ig epsilon chain C region inhibitor
MEDI-4212
×
Maximum Phase:
1
First Approval:
None
UNII:
XK0D8BK5WY
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ULOCUPLUMAB
1
Antibody
Investigational
Unknown
Unknown
Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Multiple Myeloma; Neoplasms; Waldenstrom Macroglobulinemia
C-X-C chemokine receptor type 4 inhibitor
ULOCUPLUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
7KNP87L4X4
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MANELIMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MANELIMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
U3OZ7HX207
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
3
4
5
6
7
8
9
…
27
28
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA